Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Multiple-stage procedures for drug screening.

× No keyword cloud information.

11 in total

1. Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology.

Authors: Bouke P C Hazenberg; Alexandra Croockewit; Bronno van der Holt; Sonja Zweegman; Gerard M J Bos; Michel Delforge; Reinier A P Raymakers; Pieter Sonneveld; Edo Vellenga; Pierre W Wijermans; Peter A von dem Borne; Marinus H van Oers; Okke de Weerdt; Fokje M Spoelstra; Henk M Lokhorst
Journal: Haematologica Date: 2015-02-06 Impact factor: 9.941

2. On Using Truncated Sequential Probability Ratio Test Boundaries for Monte Carlo Implementation of Hypothesis Tests.

Authors: Michael P Fay; Hyune-Ju Kim; Mark Hachey
Journal: J Comput Graph Stat Date: 2007 Impact factor: 2.302

3. A predictive probability design for phase II cancer clinical trials.

Authors: J Jack Lee; Diane D Liu
Journal: Clin Trials Date: 2008 Impact factor: 2.486

4. A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials.

Authors: Michael W Sill; Larry Rubinstein; Samuel Litwin; Greg Yothers
Journal: Clin Trials Date: 2012-07-18 Impact factor: 2.486

5. Optimal continuous-monitoring design of single-arm phase II trial based on the simulated annealing method.

Authors: Nan Chen; J Jack Lee
Journal: Contemp Clin Trials Date: 2013-03-29 Impact factor: 2.226

6. Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study.

Authors: Don S Dizon; Michael W Sill; Natalie Gould; Stephen C Rubin; S Diane Yamada; Robert L Debernardo; Robert S Mannel; Eric L Eisenhauer; Linda R Duska; Paula M Fracasso
Journal: Gynecol Oncol Date: 2011-08-05 Impact factor: 5.482

7. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Authors: Natalie Gould; Michael W Sill; Robert S Mannel; P H Thaker; Paul Disilvestro; Steve Waggoner; S Diane Yamada; Deborah K Armstrong; Lari Wenzel; Helen Huang; Paula M Fracasso; Joan L Walker
Journal: Gynecol Oncol Date: 2011-12-11 Impact factor: 5.482

8. Phase II study of N-methylformamide (N-MF) (NSC 3051) in patients with advanced epithelial ovarian cancer. A Gynecologic Oncology Group study.

Authors: W P McGuire; J A Blessing; J S Berek; A Munoz
Journal: Invest New Drugs Date: 1990-05 Impact factor: 3.850

9. A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Authors: Natalie Gould; Michael W Sill; Robert S Mannel; Premal H Thaker; Paul A DiSilvestro; Steven E Waggoner; S Diane Yamada; Deborah K Armstrong; Paula M Fracasso; Joan L Walker
Journal: Gynecol Oncol Date: 2012-08-31 Impact factor: 5.482

10. Unified exact design with early stopping rules for single arm clinical trials with multiple endpoints.

Authors: Wei Wei; Denise Esserman; Michael Kane; Daniel Zelterman
Journal: Stat Methods Med Res Date: 2021-06-23 Impact factor: 3.021